VIP Program for Risky Behaviors
Trial Summary
What is the purpose of this trial?
The purpose of this study is to review and assess the usefulness of the Values in Perspective (VIP) program to avoid adolescent risky behaviors.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the VIP Program treatment for risky behaviors?
Programs that focus on patient education and involvement in treatment, like the VIP Program, have shown positive outcomes such as reduced symptoms and increased engagement and recovery after hospitalization. Additionally, continuity of care in mental health treatments is linked to better outcomes, suggesting that structured programs can be effective.12345
How does the VIP Program treatment differ from other treatments for risky behaviors?
The VIP Program is unique because it focuses on teaching adolescents life skills and competencies to resist peer pressure and advertising influences related to smoking, alcohol, and drug use. It also involves training peer leaders to act as role models, which is different from traditional treatments that may not emphasize peer influence and social skills development.678910
Research Team
Guerda Nicolas
Principal Investigator
University of Miami
Eligibility Criteria
This trial is for English-speaking middle and high school students in grades 6-12 who live in Miami-Dade County and qualify for free or reduced lunch, indicating a lower-income household. It's not open to elementary students, those from high-income families, or non-English speakers.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a 26-week course on risk reduction strategies as part of the VIP program
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- VIP Program
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor